ArticleCureus2026

A Durable Response to Low-Dose Afatinib After Progression on Osimertinib in Advanced Epidermal Growth Factor Receptor (EGFR) L861Q-Mutated Lung Adenocarcinoma: A Case Report.

Takayuki Higashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.